Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 358

1.

Investigating the Modifications of Sugar Perception and Consumption in Cancer Patients.

Depeint F, Niamba CN, Illner AK, Buche-Foissy C, Branchu J, Younes H, Loncke C, Pouillart PR.

Nutr Cancer. 2018 Oct;70(7):1060-1068. doi: 10.1080/01635581.2018.1494844. Epub 2018 Sep 5.

PMID:
30183364
2.

Incorporation of lutein and docosahexaenoic acid from dietary microalgae into the retina in quail.

Schnebelen-Berthier C, Acar N, Pouillart P, Thabuis C, Rodriguez B, Depeint F, Clerc E, Mathiaud A, Bourdillon A, Baert B, Bretillon L, Lecerf JM.

Int J Food Sci Nutr. 2015 Mar;66(2):222-9. doi: 10.3109/09637486.2014.971227. Epub 2015 Feb 6.

PMID:
25657100
3.

Improving biological relevancy of transcriptional biomarkers experiments by applying the MIQE guidelines to pre-clinical and clinical trials.

Dooms M, Chango A, Barbour E, Pouillart P, Abdel Nour AM.

Methods. 2013 Jan;59(1):147-53. doi: 10.1016/j.ymeth.2012.07.024. Epub 2012 Aug 14.

PMID:
22910527
4.

Xylo-oligosaccharide (XOS) in combination with inulin modulates both the intestinal environment and immune status in healthy subjects, while XOS alone only shows prebiotic properties.

Lecerf JM, Dépeint F, Clerc E, Dugenet Y, Niamba CN, Rhazi L, Cayzeele A, Abdelnour G, Jaruga A, Younes H, Jacobs H, Lambrey G, Abdelnour AM, Pouillart PR.

Br J Nutr. 2012 Nov 28;108(10):1847-58. doi: 10.1017/S0007114511007252. Epub 2012 Jan 23.

PMID:
22264499
5.

Postirradiation sarcoma: clinicopathologic features and role of chemotherapy in the treatment strategy.

des Guetz G, Chapelier A, Mosseri V, Dorval T, Asselain B, Pouillart P.

Sarcoma. 2009;2009:764379. doi: 10.1155/2009/764379.

6.

Nutriose, a prebiotic low-digestible carbohydrate, stimulates gut mucosal immunity and prevents TNBS-induced colitis in piglets.

Pouillart PR, Dépeint F, Abdelnour A, Deremaux L, Vincent O, Mazière JC, Madec JY, Chatelain D, Younes H, Wils D, Saniez MH, Dupas JL.

Inflamm Bowel Dis. 2010 May;16(5):783-94. doi: 10.1002/ibd.21130.

PMID:
19998458
7.

Strategy for the study of the health impact of dietary Maillard products in clinical studies: the example of the ICARE clinical study on healthy adults.

Pouillart P, Mauprivez H, Ait-Ameur L, Cayzeele A, Lecerf JM, Tessier FJ, Birlouez-Aragon I.

Ann N Y Acad Sci. 2008 Apr;1126:173-6. doi: 10.1196/annals.1433.040.

PMID:
18448812
8.

Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases.

Fayette J, Martin E, Piperno-Neumann S, Le Cesne A, Robert C, Bonvalot S, Ranchère D, Pouillart P, Coindre JM, Blay JY.

Ann Oncol. 2007 Dec;18(12):2030-6. Epub 2007 Oct 31.

9.

Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study.

Campone M, Fumoleau P, Viens P, Diéras V, Pujade-Lauraine E, Serin D, Petit T, Espié M, Kayitalire L, Bozec L, Pouillart P.

Breast. 2006 Oct;15(5):601-9.

PMID:
17045160
10.

Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.

Laurence V, Pierga JY, Barthier S, Babinet A, Alapetite C, Palangié T, de Pinieux G, Anract P, Pouillart P.

Am J Clin Oncol. 2005 Jun;28(3):301-9. Review.

PMID:
15923805
11.

Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes--a study of 130 invasive ductal breast carcinomas.

Reyal F, Stransky N, Bernard-Pierrot I, Vincent-Salomon A, de Rycke Y, Elvin P, Cassidy A, Graham A, Spraggon C, Désille Y, Fourquet A, Nos C, Pouillart P, Magdelénat H, Stoppa-Lyonnet D, Couturier J, Sigal-Zafrani B, Asselain B, Sastre-Garau X, Delattre O, Thiery JP, Radvanyi F.

Cancer Res. 2005 Feb 15;65(4):1376-83.

12.

Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.

Diéras V, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L, Guastalla JP, Pujade-Lauraine E, Kerbrat P, Maillart P, Pénault-Llorca F, Buyse M, Pouillart P.

J Clin Oncol. 2004 Dec 15;22(24):4958-65.

PMID:
15611510
13.

Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients.

Pierga JY, Bonneton C, Magdelénat H, Vincent-Salomon A, Nos C, Boudou E, Pouillart P, Thiery JP, de Cremoux P.

Int J Cancer. 2005 Mar 20;114(2):291-8.

14.
15.

In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.

Decaudin D, de Cremoux P, Sastre X, Judde JG, Nemati F, Tran-Perennou C, Fréneaux P, Livartowski A, Pouillart P, Poupon MF.

Int J Cancer. 2005 Feb 20;113(5):849-56. Review.

16.

Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age.

Pierga JY, Girre V, Laurence V, Asselain B, Diéras V, Jouve M, Beuzeboc P, Fourquet A, Nos C, Sigal-Zafrani B, Pouillart P; Institut Curie Breast Cancer Study Group.

Breast. 2004 Oct;13(5):369-75.

PMID:
15454191
17.

Breast cancer associated with idiopathic thrombocytopenic purpura: a single center series of 10 cases.

Peffault de Latour R, Des Guetz G, Laurence V, Palangié T, Pierga JY, Diéras V, Jouve M, Extra JM, Pouillart P, Decaudin D.

Am J Clin Oncol. 2004 Aug;27(4):333-6.

PMID:
15289724
18.

[Update on docetaxel and breast cancer].

Diéras V, Girre V, Pierga JY, Laurence V, Piperno-Neumann S, Pouillart P.

Bull Cancer. 2004 May;91(5):409-17. Review. French.

19.

[Breast cancer: personalised care].

Pouillart P.

Rev Prat. 2004 Apr 30;54(8):827-9. French. No abstract available.

PMID:
15274452
20.

Paraneoplastic syndromes in cancer: Case 2. Leucocytosis associated with liposarcoma recurrence: original presentation of liposarcoma recurrence.

des Guetz G, Mariani P, Freneaux P, Pouillart P.

J Clin Oncol. 2004 Jun 1;22(11):2242-3. No abstract available.

PMID:
15169814
21.

Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma.

Decaudin D, Etienne MC, De Cremoux P, Maciorowski Z, Vantelon JM, Voog E, Urien S, Tran-Perennou C, Renée N, Vielh P, Némati F, Pouillart P.

J Natl Cancer Inst. 2004 Apr 21;96(8):636-7. No abstract available.

PMID:
15100346
22.

Prognostic value of cytokeratin 19 fragment (CYFRA 21-1) and cytokeratin-positive cells in bone marrow samples of breast cancer patients.

Pierga JY, Deneux L, Bonneton C, Vincent-Salomon A, Nos C, Anract P, Magdelénat H, Pouillart P, Thiery JP.

Int J Biol Markers. 2004 Jan-Mar;19(1):23-31.

PMID:
15077923
23.

Sternal resection and reconstruction for primary malignant tumors.

Chapelier AR, Missana MC, Couturaud B, Fadel E, Fabre D, Mussot S, Pouillart P, Dartevelle PG.

Ann Thorac Surg. 2004 Mar;77(3):1001-6; discussion 1006-7.

PMID:
14992915
24.

Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients.

Pierga JY, Bonneton C, Vincent-Salomon A, de Cremoux P, Nos C, Blin N, Pouillart P, Thiery JP, Magdelénat H.

Clin Cancer Res. 2004 Feb 15;10(4):1392-400.

25.

[Targeting epidermal growth factor receptor in cancer of the breast].

Diéras V, Pierga JY, Vincent-Salomon A, Beuzeboc P, Pouillart P, de Cremoux P.

Bull Cancer. 2003 Nov;90 Spec No:S257-62. French.

26.

Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2.

Scholl S, Squiban P, Bizouarne N, Baudin M, Acres B, Von Mensdorff-Pouilly S, Shearer M, Beuzeboc P, Van Belle S, Uzielly B, Pouillart P, Taylor-Papadimitriou J, Miles D.

J Biomed Biotechnol. 2003;2003(3):194-201.

27.

Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer.

Pierga JY, Bonneton C, Magdelénat H, Vincent-Salomon A, Nos C, Pouillart P, Thiery JP.

Br J Cancer. 2003 Aug 4;89(3):539-45.

28.

Tumor antigens and antigen-presenting capacity in breast cancer.

McDermott RS, Beuvon F, Pauly M, Pallud C, Vincent-Salomon A, Mosseri V, Pouillart P, Scholl SM.

Pathobiology. 2002-2003;70(6):324-32.

PMID:
12865628
29.

Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response.

Pierga JY, Mouret E, Laurence V, Diéras V, Savigioni A, Beuzeboc P, Dorval T, Palangié T, Jouve M, Pouillart P.

Eur J Cancer. 2003 May;39(8):1089-96.

PMID:
12736108
30.

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P; TAX 306 Study Group.

J Clin Oncol. 2003 Mar 15;21(6):968-75. Erratum in: J Clin Oncol. 2003 May 15;21(10):2048.

PMID:
12637459
31.

Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics.

Blot E, Escande MC, Besson D, Barbut F, Granpeix C, Asselain B, Falcou MC, Pouillart P.

J Hosp Infect. 2003 Mar;53(3):187-92.

PMID:
12623319
32.

Absolute lymphocyte count as a predictive factor for response to monoclonal anti-CD20 antibody therapy.

Decaudin D, Des Guetz G, Mathiot C, Dumont J, Hubert P, Vincent-Salomon A, Pouillart P.

Ann Oncol. 2003 Jan;14(1):171-2. No abstract available.

33.

Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency.

Blot E, Decaudin D, Veyradier A, Bardier A, Zagame OL, Pouillart P.

Thromb Res. 2002 Apr 15;106(2):127-30.

PMID:
12182911
34.

HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.

Vincent-Salomon A, Jouve M, Genin P, Fréneaux P, Sigal-Zafrani B, Caly M, Beuzeboc P, Pouillart P, Sastre-Garau X.

Cancer. 2002 Apr 15;94(8):2169-73.

35.

Circulating macrophage colony stimulating factor as a marker of tumour progression.

McDermott RS, Deneux L, Mosseri V, Védrenne J, Clough K, Fourquet A, Rodriguez J, Cosset JM, Sastre X, Beuzeboc P, Pouillart P, Scholl SM.

Eur Cytokine Netw. 2002 Jan-Mar;13(1):121-7.

36.

Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo.

Decaudin D, Castedo M, Nemati F, Beurdeley-Thomas A, De Pinieux G, Caron A, Pouillart P, Wijdenes J, Rouillard D, Kroemer G, Poupon MF.

Cancer Res. 2002 Mar 1;62(5):1388-93.

37.

Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.

Dieras V, Bougnoux P, Petit T, Chollet P, Beuzeboc P, Borel C, Husseini F, Goupil A, Kerbrat P, Misset JL, Bensmaïne MA, Tabah-Fisch I, Pouillart P.

Ann Oncol. 2002 Feb;13(2):258-66.

38.

Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients.

Misset JL, Vennin P, Chollet PH, Pouillart P, Laplaige PH, Frobert JL, Castera D, Fabro M, Langlois D, Cortesi E, Lucas V, Gamelin E, Laadem A, Otero J.

Ann Oncol. 2001 Oct;12(10):1411-5.

39.

Interaction between Herceptin and taxanes.

Diéras V, Beuzeboc P, Laurence V, Pierga JY, Pouillart P.

Oncology. 2001;61 Suppl 2:43-9. Review.

PMID:
11694787
40.

Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors.

Foncuberta MC, Cagnoni PJ, Brandts CH, Mandanas R, Fields K, Derigs HG, Reed E, Sonis ST, Fay J, LeVeque F, Pouillart P, Schrezenmeier H, Emmons R, Thiel E; Investigators in TGF-beta3/OM Study Protocols 203/205.

J Immunother. 2001 Jul-Aug;24(4):384-8.

PMID:
11565840
41.

Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery.

Rouzier R, Extra JM, Carton M, Falcou MC, Vincent-Salomon A, Fourquet A, Pouillart P, Bourstyn E.

J Clin Oncol. 2001 Sep 15;19(18):3828-35.

PMID:
11559720
42.

Targeting HER2 in other tumor types.

Scholl S, Beuzeboc P, Pouillart P.

Ann Oncol. 2001;12 Suppl 1:S81-7. Review.

43.

Distinct experimental efficacy of anti-Fas/APO-1/CD95 receptor antibody in human tumors.

Decaudin D, Beurdeley-Thomas A, Nemati F, Miccoli L, Pouillart P, Bourgeois Y, Gonçalves RB, Rouillard D, Poupon MF.

Exp Cell Res. 2001 Aug 15;268(2):162-8.

PMID:
11478842
44.

Long term outcome of small size invasive breast carcinomas independent from angiogenesis in a series of 685 cases.

Vincent-Salomon A, Carton M, Zafrani B, Fréneaux P, Nicolas A, Massemin B, Fourquet A, Clough K, Pouillart P, Sastre-Garau X.

Cancer. 2001 Jul 15;92(2):249-56.

PMID:
11466676
45.

[Hepatic resection for breast cancer metastases: results and prognosis (65 cases)].

Pocard M, Pouillart P, Asselain B, Falcou MC, Salmon RJ.

Ann Chir. 2001 Jun;126(5):413-20. French.

PMID:
11447791
46.

Single-agent gemcitabine is active in previously treated metastatic breast cancer.

Spielmann M, Llombart-Cussac A, Kalla S, Espié M, Namer M, Ferrero JM, Diéras V, Fumoleau P, Cuvier C, Perrocheau G, Ponzio A, Kayitalire L, Pouillart P.

Oncology. 2001;60(4):303-7.

PMID:
11408796
47.

Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.

Namer M, Soler-Michel P, Turpin F, Chinet-Charrot P, de Gislain C, Pouillart P, Delozier T, Luporsi E, Etienne PL, Schraub S, Eymard JC, Serin D, Ganem G, Calais G, Maillart P, Colin P, Trillet-Lenoir V, Prevost G, Tigaud D, Clavère P, Marti P, Romieu G, Wendling JL.

Eur J Cancer. 2001 Jun;37(9):1132-40.

PMID:
11378344
48.

Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients.

Pierga JY, Robain M, Jouve M, Asselain B, Diéras V, Beuzeboc P, Palangié T, Dorval T, Extra JM, Scholl S, Pouillart P.

Ann Oncol. 2001 Feb;12(2):231-7.

49.

Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy.

Pierga JY, Asselain B, Jouve M, Diéras V, Carton M, Laurence V, Girre V, Beuzeboc P, Palangié T, Dorval T, Pouillart P.

Cancer. 2001 Mar 15;91(6):1079-89.

PMID:
11267952
50.

Modulation of MHC class II transport and lysosome distribution by macrophage-colony stimulating factor in human dendritic cells derived from monocytes.

Baron C, Raposo G, Scholl SM, Bausinger H, Tenza D, Bohbot A, Pouillart P, Goud B, Hanau D, Salamero J.

J Cell Sci. 2001 Mar;114(Pt 5):999-1010.

Supplemental Content

Loading ...
Support Center